Cirrhosis — Clinical Documentation Guide (2026)

This Clinical Documentation Guide (CDG) provides certified coders and clinical documentation integrity (CDI) specialists with comprehensive coding, clinical, and documentation guidance for cirrhosis and end-stage liver disease. Content reflects FY2026 ICD-10-CM guidelines effective October 1, 2025, and incorporates current clinical standards, HCC v28 risk-adjustment mapping, and AHIMA/ACDIS-compliant CDI query templates.

🔍 1. Definition

Cirrhosis is the end-stage result of chronic hepatic injury characterized by diffuse fibrosis, destruction of the normal hepatic parenchymal architecture, and formation of regenerative nodules. It represents a common pathway for many chronic liver diseases and is associated with significant morbidity from portal hypertension, hepatocellular dysfunction, and multiorgan complications, as described by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Cirrhosis is classified as compensated (no major complications) or decompensated (presence of ascites, variceal bleeding, hepatic encephalopathy, or jaundice). Decompensated cirrhosis carries a 1-year mortality of approximately 20–57% depending on the degree of organ dysfunction, per AASLD Practice Guidance on Cirrhosis (2021).

MELD-Na Scoring

The Model for End-Stage Liver Disease – Sodium (MELD-Na) score is the primary prognostic tool for cirrhosis severity and transplant prioritization. It incorporates serum bilirubin, creatinine, INR, and sodium. As of 2022, UNOS/OPTN uses MELD-Na for liver allocation. Score ranges: <10 (compensated, low near-term mortality), 10–19 (moderate), 20–29 (high), ≥30 (critical/transplant priority).

Child-Pugh Classification

The Child-Pugh score (also Child-Turcotte-Pugh) assesses hepatic reserve using bilirubin, albumin, INR/PT, ascites severity, and degree of encephalopathy. It stratifies patients into Class A (5–6 points; compensated), Class B (7–9 points; significant dysfunction), and Class C (10–15 points; decompensated/end-stage), per MDCalc. Class C carries a 1-year survival of approximately 45%.

🗂️ 2. Alternative Terminology

Coders and CDI specialists will encounter the following terms in clinical documentation that map to cirrhosis codes in ICD-10-CM:

🩺 3. Signs & Symptoms

Cirrhosis presents across a wide clinical spectrum depending on whether the disease is compensated or decompensated. Clinical signs and symptoms documented in the medical record drive code selection and CDI query opportunities.

Compensated Cirrhosis

• Fatigue, malaise, and weakness
• Spider angiomata and palmar erythema
• Mild hepatomegaly or, later, small nodular liver
• Gynecomastia and testicular atrophy (men)
• Thrombocytopenia (hypersplenism)
• Mildly elevated bilirubin, AST, ALT, alkaline phosphatase

Decompensated Cirrhosis

• Ascites: Abdominal distension, flank dullness, fluid wave; may be complicated by spontaneous bacterial peritonitis (SBP)
• Esophageal/gastric varices: Hematemesis, melena, hematochezia — acute variceal bleeding is a life-threatening emergency
• Hepatic encephalopathy (HE): Confusion, asterixis, altered consciousness ranging from subtle personality changes to coma
• Jaundice: Scleral icterus, skin yellowing, dark urine, pale stools
• Coagulopathy: Easy bruising, prolonged PT/INR, risk of bleeding
• Hepatorenal syndrome (HRS): Progressive azotemia, oliguria in absence of other renal pathology
• Hepatopulmonary syndrome / Portopulmonary hypertension: Dyspnea, hypoxemia
• Sarcopenia and cachexia: Muscle wasting, weight loss, frailty

🧭 4. Differential Diagnosis

The following conditions may present similarly to cirrhosis or complicate coding decisions when multiple diagnoses are present:

📋 5. Clinical Indicators for Coders/CDI

The following clinical indicators in the medical record should prompt code assignment or CDI query initiation for cirrhosis and its complications:

🦴 6. Anatomy & Pathophysiology

The liver is the largest solid organ, weighing approximately 1,400–1,600 g in adults. It is divided into right and left lobes and receives dual blood supply: the portal vein (~75% of inflow, nutrient-rich from gut) and the hepatic artery (~25%, oxygenated). Blood drains via the hepatic veins into the inferior vena cava, as reviewed in StatPearls: Liver Anatomy (NCBI).

Pathogenesis of Cirrhosis

1. Chronic injury: Repeated hepatocyte damage from alcohol, viral infection (HBV/HCV), metabolic dysfunction (MASLD/NASH), autoimmune processes, cholestasis, or toxins activates hepatic stellate cells (HSCs).
2. Stellate cell activation: Quiescent HSCs transform into myofibroblasts, secreting excess collagen (primarily type I and III) and other extracellular matrix proteins — the hallmark of fibrogenesis.
3. Fibrosis progression: Fibrosis advances from portal (F1) → periportal bridging (F2–F3) → cirrhosis (F4, Metavir scale), replacing normal hepatic architecture with fibrous septa and regenerative nodules per AASLD.
4. Portal hypertension: Disrupted vascular architecture increases intrahepatic resistance → elevated portal venous pressure (>12 mmHg defines clinically significant portal hypertension) → portosystemic shunting → esophageal/gastric varices, splenomegaly, ascites.
5. Hepatocellular dysfunction: Reduced synthetic capacity manifests as hypoalbuminemia, coagulopathy (reduced clotting factors II, V, VII, IX, X), impaired ammonia metabolism → encephalopathy, hyperbilirubinemia.
6. Systemic inflammation: Bacterial translocation from gut activates systemic immune response, driving SIRS, acute-on-chronic liver failure (ACLF), and multi-organ dysfunction.

Complications Pathophysiology

• Hepatorenal syndrome (HRS): Splanchnic vasodilation → reduced effective circulating volume → renal vasoconstriction → functional renal failure. HRS-AKI (formerly type 1) is rapid; HRS-CKD (formerly type 2) is slower.
• Spontaneous bacterial peritonitis (SBP): Bacterial translocation across gut mucosa into ascitic fluid; most commonly E. coli, Klebsiella, enterococci.
• Hepatic encephalopathy: Ammonia and other gut-derived toxins cross blood-brain barrier due to impaired hepatic clearance and portosystemic shunting; glutamine accumulation in astrocytes → cerebral edema.

💊 7. Medication Impact / Treatment

Medications used in cirrhosis management directly influence CDI queries, code assignment, and MS-DRG complexity. The following drugs are commonly encountered in cirrhosis-related encounters:

Portal Hypertension / Variceal Prophylaxis

• Non-selective beta-blockers (propranolol, nadolol, carvedilol): First-line primary and secondary prophylaxis for variceal bleeding; documented indication drives K76.6 portal HTN coding query. Per AASLD guidelines, carvedilol is preferred for primary prophylaxis.
• Vasopressin analogues (octreotide, terlipressin): Acute variceal bleeding management; IV octreotide initiates at 50 mcg bolus then 25–50 mcg/hr infusion.

Ascites Management

• Diuretics (spironolactone ± furosemide): Standard therapy; spironolactone 100 mg + furosemide 40 mg titrated upward per AASLD stepwise protocol.
• Albumin infusion: Used post-large-volume paracentesis (>5 L) to prevent circulatory dysfunction; also used in SBP (1.5 g/kg day 1, 1 g/kg day 3) to reduce HRS risk.
• Tolvaptan: Vasopressin V2 receptor antagonist for hyponatremic ascites; use limited due to hepatotoxicity risk.

Hepatic Encephalopathy

• Lactulose: Reduces ammonia absorption; titrate to 2–3 soft stools/day. Presence in medication record is a CDI trigger for HE documentation.
• Rifaximin (Xifaxan): Non-absorbable antibiotic; reduces gut ammonia-producing bacteria; standard adjunct for recurrent HE. Per FDA prescribing information, indicated for overt HE reduction in adults.
• Zinc supplementation: Zinc deficiency is common in cirrhosis; affects urea cycle.

Infection Prophylaxis / SBP Treatment

• Norfloxacin / ciprofloxacin / trimethoprim-sulfamethoxazole: Long-term SBP prophylaxis in patients with low-protein ascites or prior SBP episode.
• Cefotaxime / ceftriaxone: Empiric treatment for diagnosed SBP.

Anticoagulation Considerations

• Cirrhosis causes a rebalanced coagulation state (both pro- and anticoagulant factors reduced); elevated INR does not reliably indicate bleeding risk. Anticoagulation may be used for portal vein thrombosis (PVT) with LMWH or direct oral anticoagulants per hepatologist guidance.

Liver Transplant Immunosuppression

• Tacrolimus, mycophenolate mofetil, prednisone: Standard post-transplant regimen; ongoing medication requires Z94.4 (liver transplant status) coding in follow-up encounters.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides